Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuvo Research, a Canadian drug development company, has announced that fqubed, its San Diego-based R&D subsidiary, has signed a R&D collaboration agreement with a Fortune Global 500 company that develops and markets skin care products. Financial details of the agreement were not disclosed.
Subscribe to our email newsletter
Under the collaboration, fqubed will expand the scope of its Tempest high throughput experimentation platform to evaluate potential formulations for its partner’s product portfolio. Tempest is currently used to screen the impact that formulation variations have on the penetration of a drug molecule through skin.
Dan Chicoine, Nuvo’s chairman, said: “The fqubed technologies have valuable applications beyond our primary focus on pharmaceutical products delivered to and through the skin.
“Collaboration agreements such as this allow us to leverage the power of our transdermal screening and high throughput formulation development platforms in complementary areas, and to improve our research capabilities so that we can more effectively develop our own topical drug pipeline.”